BioSpace News Archive

MicroVention, Inc., a U.S.-based subsidiary of Terumo and a global neurovascular company, announced today the FDA Approval of the PMA Supplement for the WEB 17 System, a new addition to the WEB Aneurysm Embolization System for the treatment of intracranial wide neck bifurcation aneurysms.

Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process Hesperidin may help against Covid-19 viral replication Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced the completion of patient enrollment in the LIFT study, a Phase 2a NASH clinical trial of TERN-101,

Anticipates $2.3 Million Revenue in Fourth Quarter, $8.5 Million in Full-Year; Quarterly Revenue Grew 9% Sequentially Over Third Quarter; Full Year Revenue Declined 17%

The U.S. Food and Drug Administration has granted Emergency Use Authorization (EUA) to one of the first U.S.-manufactured serology tests designed by ADVAITE Inc., an innovative biotech company developing novel point-of-care assays to help with combatting COVID-19

Ocugen, Inc. announced it has determined to withdraw from stockholder consideration Item 2 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on October 30, 2020, with respect to an increase in the number of shares of common stock authorized for issuance under the Company’s Sixth Amended and Restated Certificate of Incorporation.

TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it has entered into securities purchase agreements with several institutional investors for the purchase and sale, in a registered direct offering of 25,000,000 shares of its common stock at a purchase price of $1.25 per share for gross proceeds of $31.25 million.

Leading retina clinician Dr. Rahhal discusses the market need for an FDA-approved ophthalmic bevacizumab for treating wet AMD and other retinal diseases

Cocrystal Pharma, Inc., a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics, announces that management will present at NobleCon17, Noble Capital Markets’ 17th Annual Investor Conference on Tuesday, January 19, 2021 at 2:15 p.m. Eastern time.

AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2020 financial results on Wednesday, February 3, 2021, before the market opens